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Most of the SOD mimics thus far developed belong to the classes of Mn-(MnPs) and Fe porphyrins(FePs),
Mn(III) salens, Mn(II) cyclic polyamines and metal salts. Due to their remarkable stability we have pre-
dominantly explored Mn porphyrins, aiming initially at mimicking kinetics and thermodynamics of the
catalysis of O2d dismutation by SOD enzymes. Several MnPs are of potency similar to SOD enzymes. The
in vivo bioavailability and toxicity of MnPs have been addressed also. Numerous in vitro and in vivo
studies indicate their impressive therapeutic efﬁcacy. Increasing insight into complex cellular redox
biology has been accompanied by increasing awareness of complex redox chemistry of MnPs. During
O2
d dismutation process, the most powerful Mn porphyrin-based SOD mimics reduce and oxidize O2
d
with close to identical rate constants. MnPs reduce and oxidize other reactive species also (none of them
speciﬁc to MnPs), acting as reductants (antioxidant) and pro-oxidants. Distinction must be made between the
type of reactions of MnPs and the favorable therapeutic effects we observe; the latter may be of either anti- or
pro-oxidative nature. H2O2/MnP mediated oxidation of protein thiols and its impact on cellular tran-
scription seems to dominate redox biology of MnPs. It has been thus far demonstrated that the ability of
MnPs to catalyze O2d dismutation parallels all other reactivities (such as ONOO reduction) and in turn
their therapeutic efﬁcacies. Assuming that all diseases have in common the perturbation of cellular redox
environment, developing SOD mimics still seems to be the appropriate strategy for the design of potent
redox-active therapeutics.
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The necessity of SOD enzymes for all aerobic life [1,2] led to the
development of SOD mimics as therapeutics [3]. The macrocyclicScheme I. The O2d dismutation process catalyzed by pentacationic Mn porphyrins (A)
Mn complexes involves MnIII/MnII redox couple. The dismutation process shown here comm
actions during O2d dismutation, i.e. they can accept (1st step) electron from O2d prod
H2O2 if their metal-centered reduction potential, E1/2 for MnIIIP/MnIIP redox couple is w
mimics are mild oxidants and reductants/antioxidants and that their reduction potential
targets. Yet, there is another side of dismutation process. The 2nd step (while antioxidati
and their mimics may in turn be only viewed as anti-oxidative defense when (under phy
why in numerous in vivo reactions (oxidation of thiols, ascorbate, lipids, NADPH, NADH, see
additional distinction must be made here between the actions of redox-active compounds an
vs NHE (very electron rich such as MnTBAP3 or MnTSPP3) are fairly redox-inert and c
during oxidation with strong oxidants (such as ONOO , ClO , lipid reactive species). Sinc
Mn site, such reactions are less favored than those with electron-deﬁcient Mn porphyri
Note, also that MnPs with E1/24þ450 (very electron-deﬁcient, MnIIBr8TM-3(or 4)-PyP4þ
pH 7.8. For comparison those Mn(III) N-alkylpyridylporphyrins with Mn in þ3 oxidation
compounds therefore start dismutation by reducing O2d while oxidizing Mn in a 1s
Scheme A. B. Dismutation of O2d by Mn(III) biliverdin and its analogs employ MnIV/M
Mn(III)- and Fe(III) corroles employ metal þ3/þ4 redox couple also [8]. In turn, in a 1st
whereas in backward reaction they get reduced with O2d (and restored as catalysts) (s
þ4), O2d only cares if the metal easily accepts electron from and donates the electron
oxidation and reduction of O2d; consequently both steps of dismutation are facilitated t
vs NHE for Mn(III) biliverdin analogs, while E1/2¼þ468 and þ480 mV vs NHE for Br8Mstructure of a porphyrin ring, by the analogy to the structure of the
critical porphyrin-containing proteins, such as hemoglobin, myo-
globin, nitric oxide synthases and cyt P450 family of enzymes,
provides limitless stability to a metal complex and preservesand Mn biliverdin (and its derivatives) (B). A. Dismutation of O2d by pentacationic
unicates important information that SOD mimics exhibit PRO- and ANTI-oxidative
ucing O2, and give away electron to another molecule of O2d (2nd step) producing
ithin the range of þ100 to þ500 mV vs NHE. Such E1/2 values indicate that SOD
s are biologically compatible and allow them to couple with numerous other biological
ve in its nature with regards to O2d) produces an oxidant, H2O2. The SOD enzymes
siological conditions) are coupled with multiple H2O2 removing systems. It explains
below) MnP acts as pro-oxidant, while still GENERATING therapeutic EFFECTS. Thus the
d therapeutic effects observed. Please note that MnPs with very negative E1/2o0 mV
annot be reduced in a 1st step with O2d , but can act as anti-oxidants (reductants)
e they are electron-rich, and oxidation with those species involves their binding to
ns (such as MnTE-2-PyP5þ) with E1/2 in between þ100 and þ500 mV vs NHE [7].
and Cl5MnIITE-2-PyP4þ), are stabilized in þ2 oxidation state and lose Mn readily at
state (indicated with III) resist even 98% sulfuric and 36% hydrochloric acids. Such
t step, and get reduced to Mn(II) while oxidizing O2d in a 2nd step, reversal of
nIII redox couple, shown in Scheme for Mn(III) biliverdin dimethylester (BVDME).
step those metal sites reduce O2d while undergoing oxidation to M(IV) complex,
ee [3] for details). Regardless of which metal redox couple is used (þ3/þ2 or þ3/
to it, thus operating at E1/2 value that is around the midway potential between the
o a similar extent. That indeed is true, the E1/2 ranges between þ440 and þ470 mV
nIITM-3-PyP4þ for Br8MnIITM-4-PyP4þ [9].
I. Batinic-Haberle et al. / Redox Biology 5 (2015) 43–65 45integrity of the metal site where all actions occur. Consequently,
porphyrin appears to be the most appropriate ligand for an SOD
mimic. Further, the porphyrin structure allows for limitless mod-
iﬁcations whereby the redox property, bioavailability and toxicity
could be optimized. Over years in search for the best therapeutics,
metalloporphyrins with high kcat(O2d) reaching that of SOD en-
zyme and with high stability towards the loss of Mn, have been
synthesized and characterized. Such properties give them the
advantage over other classes of SOD mimics. Most recent research
indicate that SOD-like activity parallels ability of MnPs to undergo
other reactions (such as ONOO reduction) and their therapeutic
efﬁcacy. None of the reactions appear speciﬁc to MnPs. For addi-
tional insight see also other articles in Antioxidant & Redox Sig-
naling 2014 Forum Issues on “Superoxide dismutases” (vol. 20/10)Scheme II. SOD mimics were designed in a process where the kinetics and thermodyna
kinetics of the catalysis O2
d dismutation relates to the electrostatic facilitation of the a
superoxide is pulled towards the metal site through the tunnel of amino acids with ca
2.5 orders of magnitude faster catalysts than those which are either neutral or anionic a
the metal site (described with metal-centered reduction potential, E1/2) which would all
Cationic compounds with E1/2 for MnIIIP/MnIIP redox couple around the E1/2 of SOD enzym
O2d dismutation in aqueous solution with high rate constants. In addition, they are ex
mimics sits around the midway potential between the E1/2 for O2d reduction at þ890 m
for both steps of dismutation process [3,9]. Indeed both steps occur with the same rate c
The most powerful SOD mimics belong to the class of Mn(III) ortho (N-substituted py
4 positive charges at the periphery to attract O2d , and favorable thermodynamics, E1/2
which are β-halogenated (with chlorines at β positions of pyrrole rings, see Scheme IV)
stable. Adapted from [3].and “SOD therapeutics” (vol.20/15).O2d dismutation process
The dismutation process consists of two steps indicated below
for Mn porphyrin-based SOD mimics. It is critical to note that:
(i) SOD enzyme or MnP-based mimic acts as a (pro)oxidant in a 1st
step, and as an anti-oxidant in a 2nd step, whereby closing the
catalytic cycle, and (ii) an oxidant, H2O2, is produced in a 2nd step.
Under physiological conditions it is taken care of. Thus, H2O2 is
either dismuted to O2 and H2O2, or H2O2 is reduced to H2O, with
enzymatic systems such as catalases, glutathione peroxidases
(GPx), peroxiredoxins, etc. Therefore both SOD and its mimic couldmics of O2d dismutation catalyzed by superoxide dismutases were mimicked. The
pproach of anionic O2d towards the metal site. In the case of enzyme the anionic
tionic residues. Those MnPs which have cationic charges on periphery are 2 or
t the periphery, respectively. The thermodynamics relates to the redox properties of
ow Mn to equally easily accept electron from one O2d and give it to another O2d .
es (þ300 mV vs NHE) were synthesized and demonstrated to efﬁciently catalyze
tremely stable complexes towards the loss of Mn. Such E1/2 of SOD enzyme and its
V vs NHE and its oxidation at 180 mV vs NHE. In turn, it allows equal facilitation
onstants with SOD enzyme as was demonstrated for its mimic, MnTE-2-PyP5þ [10].
ridinium-2-yl)porphyrins. They possess both favorable electrostatics, as they bear
þ200 to þ450 mV vs NHE. Among them the ortho, meta and para pyridyl MnPs
possess the highest kcat(O2d), close to that of SOD enzymes; yet they are the least
I. Batinic-Haberle et al. / Redox Biology 5 (2015) 43–6546be considered an antioxidative defense only when coupled to H2O2
removing systems. Growing data indicate that in cancer such
systems fail. Reports indicate downregulation or inactivation of
enzymes such as GPx and peroxiredoxin, while up-regulation of
SOD during cancer progression [4–6]. In turn, H2O2 gets accumu-
lated and used by cancer cell for its proliferation; under such
conditions both SOD and its mimic will increase oxidative stress
and cannot be anymore considered an antioxidative defense
[3,5,6].Design of SOD mimics
MnP-based SOD mimics have been developed with the goal to
mimic the kinetics and thermodynamics of the catalysis of O2d
dismutation by SOD enzymes (Scheme II and III). MnPs, which
kcat(O2d) is close to that of enzyme, were synthesized:
Br8MnTM-3-PyP4þ(log kcat(O2d) Z8.85), Br8MnTM-4-PyP4þ
(log kcat(O2d) Z8.67) and Cl5MnTE-2-PyP4þ(log kcat(O2d)¼8.41)
(Scheme VI). Such results teach us that even with low-molecular
weight compounds the properties of an enzyme could be mimicked.
The log kcat(O2d) of SOD enzymes in the range 8.84–9.30 were
reported [1,9]. Yet the protein structure assures the speciﬁcity of SOD
enzymes to O2d . Despite favorable thermodynamics, the SOD en-
zymes react with other species, such as ONOO , orders of magnitude
slower than cationic MnTE-2-PyP5þ .
Over years diverse compounds were synthesized and/or ob-
tained from commercial sources of either high, modest or no SOD-
like activities. Mn porphyrins with high (log kcat(O2d)47),Scheme III. The design of SOD mimics occurred through phases I to IV. The unsubstituted
vs NHE which is too negative (more negative than E1/2¼180 mV vs NHE for O2d oxida
dismutation process. In addition, there is no electrostatic facilitation; subsequently it has
density to enable its acceptance of electron and reduction with O2d , the alkyl groups we
withdrew the electron density fromMn site. In turn, Mn becomes electron-deﬁcient and p
modest log kcat(O2d)¼6.58. Such rate constant is still 3.5 orders of magnitude low
(2) positions in Phase II moves positive charges closer to Mn site, which enhances both t
Mn porphyrin. In turn, E1/2 of MnTM-2-PyP5+ is increased for another order of magnitude,
or below the porphyrin plane and suppress the interaction of MnP with nucleic acid [11]. S
activity and may impose toxicity. Ortho isomers exist as 4 atropoisomers which all have
Once the knowledge on key ortho impact has been gained, ortho N-ethylpyridyl analog
were synthesized in Phase II and Phase IIa and are among the most frequently studied com
hydrophilic. Initial studies suggested that, by increasing lipophilicity, we should be able
cationic charge is a driving force, lipophilicity is another major factor that affects their tr
their therapeutic efﬁcacy [80–82,89]. The lipophilicity was addressed in Phase III. Several
lipophilic than MnTE-2-PyP5+) has been the most frequently studied in vitro and in vivo.
higher ability to damage lipid membranes. This is however outbalanced with the much h
doses are needed for the efﬁcacies identical to those produced by hydrophilic MnTE-2-PyP
analog [13]. The micellar property and in turn toxicity was suppressed by 4–5-fold re
chains: MnTnBuOE-2-yP5þ was synthesized in Phase IV [14] and has been aggressively dmodest log kcat(O2d)o7 and no SOD-like activity (log kcat(O2d)
r5.6) are listed in Schemes IV, V and VII. Those of no SOD-like
activities have been often incorrectly used to support O2d-related
pathways.Structure–activity relationships, SAR, for mimicking SOD
enzymes
See Scheme VI.Mn porphyrin-based non-SOD mimics
See Scheme VII.Fe porphyrin-based SOD mimics
See Scheme VIII.Reactivities of MnPs towards diverse low-molecular weight
reactive species
The reactivity of ortho Mn(III) N-substituted pyridylporphyrin
towards a whole spectrum of reactive species with corresponding
rate constants (estimated based on reactions of MnTE-2-PyP5þ) iselectron-rich MnT-4-PyPþ has E1/2 value for MnIIIP/MnIIP redox couple of 200 mV
tion) and precludes its reduction (along with O2d oxidation) to start the 1st step of
no SOD like activity, log kcat(O2d)¼4.53. In order to decrease metal center electron
re added to pyridyl nitrogens in Phase I; subsequently nitrogens became cationic and
rone to be reduced at biologically feasible Ε1/2 of þ60 mV vs NHE, which results in a
er than that of SOD enzyme. Shifting nitrogens from para (4) positions to ortho
he electron-withdrawing effects and the attraction of anionic superoxide to cationic
log kcat(O2d)¼7.79. Very importantly alkyl chains in ortho positions are stuck above
uch interaction demonstrated with planar para MnTM-4-PyP5þ prevent its SOD-like
the same E1/2 and same log kcat(O2d), but likely have different biodistribution [12].
MnTE-2-PyP5þ and its di-ortho N,N′-diethylimidazolyl derivative, MnTDE-2-ImP5þ ,
pounds both in vitro and in vivo. Both compounds are pentactionic and thus highly
to enhance their accumulation within organs and cells and mostly so brain. While
ansport across the blood brain barrier and mitochondrial accumulation and in turn
lipophilic compounds have been synthesized. MnTnHex-2-PyP5þ (~6,500-fold more
The longer the hydrophobic alkyl chains the higher their micellar properties and the
igher accumulation of MnTnHex-2-PyP5þ within cell; in turn, up to 120-fold lower
5þ . This further allowed for a wider therapeutic window for the hexyl than for ethyl
lative to MnTnHex-2-PyP5þ when polar oxygen atoms were introduced into alkyl
eveloped towards clinic.
I. Batinic-Haberle et al. / Redox Biology 5 (2015) 43–65 47summarized in Scheme IX. The related reactions are described by
equations in Scheme X. These reactions may dominate their in-
vivo actions and may not necessarily be related to SOD mimicking.
Most of those reactions are not catalytic, and their rate constants
refer to either reduction or oxidation of MnP, i.e. or oxidation or
reduction of respective reactive species. The reactivities of MnPs
could become catalytic in vivo, i.e. MnP as a catalyst could be re-
covered. This could happen when the reduction or oxidation of
MnP is coupled with other reactive species or cellular reductant. In
addition to direct reactions with small reactive species listed in
Schemes IX and X, MnPs react directly with small thiols such as
GSH and cysteine and with protein thiols of signaling proteins/
transcription factors (Schemes XI and IV) as well as with ascorbate
(Scheme XII) and tetrahydrobiopterin (Scheme XIII). MnPs inter-
actions with thiols may or may not involve H2O2. If driven by H2O2,
various MnP redox couple will be involved (Schemes XI, XII and
XIV). MnP/H2O2-mediated oxidation of NADH and NADPH was
demonstrated also (Scheme XIV).Scheme IV. Powerful Mn porphyrin-based SOD mimics (log kcat(O2d)>7). The most p
which carry positive charges to guide anionic O2d to the metal site and tune E1/2 to be in
[3,9,15].Researchers need to pay attention to the type of rate constants
they refer to. Immediate translation of data from aqueous solutions to
cellular and animal models is not straightforward and often requires
substantial insight into extremely complex chemistry of those redox
active drugs, their biodistribution (affected by their lipophilicities,
polarities, charge, size and bulkiness) at sufﬁcient concentrations and
at targeted location [3,5,9,15,22–24].Reactivity of MnPs towards cellular reductants – thiols, ascor-
bate and tetrahydrobiopterin
The interactions of Mn(III) ortho N-substituted pyridylporhyrins
with cellular reductants seems to play critical role in the biology of
MnPs, in great part due to high levels of cellular reductants. Such
interactions have been explored in aqueous solutions, in vitro and
in vivo and are depicted in Schemes IX–XIV [3,18,30,40–44]. Such
interactions also play major role in MnP/H2O2 biology depictedowerful compounds bear ortho cationic pyridyl- or di-ortho imidazolyl nitrogens
between þ200 and þ500 mV vs NHE. For numerical values of kcat(O2d) please see
I. Batinic-Haberle et al. / Redox Biology 5 (2015) 43–6548in Schemes XIV, XVII and XIX.Role of H2O2 in the actions of MnPs
While MnPs are not functional mimics of catalase [30], H2O2
seems to be critical in the redox biology of MnPs. MnP produces
H2O2 in a reaction of reduced MnIIP with oxygen, O2 (Eq. (7) in
Scheme X) and superoxide, O2d during cycling with either thiol
or ascorbate or tetrahydrobiopterin (Schemes XI, XII, XIII). Subse-
quently it can use it to oxidize biological targets listed in
Scheme XIV. Such scenario may allow for maintenance of the
(unchanged) levels of H2O2; this was indeed demonstrated by
Tome's group in lymphoma studies when lymphoma cells were
treated with MnP/dexamethasone [43]. Many aspects of H2O2 in
the biology of MnPs are listed in Scheme XIV; there may still be
reactions which we have not yet explored. Present data point to a
complex MnP redox-biology.Scheme V. Modest mimics of SOD enzymes (log kcat(O2d)= 5.7–7). Some of those com
and compensates largely for their inferior SOD-like activity. That has been most strikingly
10-fold lower kcat(O2d), but with 10 fold higher cellular accumulation, MnTE-3-PyP5þ p
kcat(O2d) please see [3,9,15].SOD-like activity parallels all other reactivities and in turn
controls therapeutic effects of MnPs
We came a long way-from SOD mimicking to H2O2-related pathways
We initially believed that MnPs are speciﬁc SOD mimics. In
2006, Dr. Radi approached us at the 13th Annual Meeting of the
SFRBM suggesting that MnPs may react with ONOO also. Per-
oxynitrite was an emerging species at that time. Intuitive rea-
soning would say that nature would not make a more dangerous
species from two less dangerous and physiologically important
radicals, O2d and dNO. Moreover, it seems that nature has not
developed an enzymatic system which could take care of ONOO
speciﬁcally, unless peroxiredoxins serve that purpose [56,57]. The
studies on ONOO in collaboration with Radi's group reveal that
reactivities towards ONOO and O2d are similar, only few fold
away from each other [7,58]. That has opened the door to con-
siderations that MnPs may play crucial role in in vivo destiny of
reactive species other than O2d . Along with the growing aware-
ness of H2O2 as a central modulator in cellular redox processes, thepounds have increased lipophilicity which allows higher intracellular accumulation
demonstrated with orthoMnTE-2-PyP5þ and itsmeta isomer, MnTE-3-PyP5þ . With
rotected SOD-deﬁcient E. coli to the same extent as did MnTE-2-PyP5þ . For values of
Scheme VI. (A) Structure–activity relationships, SARs, relate E1/2 to log kcat(O2d) for cationic, anionic and compounds which are neutral on periphery. All MnIIIPs carry
oneþcharge on Mn center. SARs have been initially established for Mn porphyrins and later proven to have wider applicability to any redox active metal complex (Scheme
VIB). As compared to cationic MnPs, the 2–2.5 orders of magnitude lower kcat(O2d) was determined with neutral or anionic compounds than with cationic MnPs, where
either no attraction exists or anionic O2d is repulsed from anionic porphyrin. The additional importance of such SARs lies in the fact that the magnitude of the interactions
of SOD mimics with other reactive species (thus far explored, Schemes IX–XIV), and their therapeutic effects are directly proportional to their SOD-like activity; in turn SAR
established for SOD-like activity, can offer best guidance for the development of powerful therapeutics. Compounds which dismute O2d with rate constants lower than that for
self-dismutation, log kcat(O2d)o5.7, are not mimics of SOD. A number of Mn porphyrins with no SOD-like activities reportedly demonstrate beneﬁcial therapeutic effects in
vitro and in vivo models of diseases (Scheme XXV). Such data suggest that mechanism of action, other than SOD-like, may be operative [4]. Adapted from [16]. (B) Structure
activity relationships, SARs, relates E1/2 to log kcat(O2d) for all compounds irrespectively of their electrostatics, their size and shape and type of redox couple involved. The
blue curve relates to all compounds irrespective of the type of redox couple involved: either Mn(III)/Mn(II) or Mn(IV)/Mn(III). The O2d does not care which type of redox
couple is involved, as long as the magnitude of E1/2 is adequate. The red dashed curve relates to the compounds which operate via Mn(III)/Mn(II) redox couple, while the
green one relates to compounds that utilize Mn(IV)/Mn(III) redox couple for O2d dismutation. While we have not explored it further, the maximum seems to be shifted right
for compounds which use Mn(IV)/Mn(III) redox couple; therefore the dashed curves are suggested. The larger deviation from the plot is demonstrated with compounds
which have unfavorable electrostatics (anionic, bulky compounds). The largest deviation is seen with non-metal-based SOD mimics such as nitroxides. When the E1/2 is very
negative, left arm of bell-shape curve, the reduction of MnIIIP to MnIIP is a rate limiting step in O2d dismutation. As the E1/2 increases, reaching maximal log kcat values, both
steps of dismutation become similar and offer similar thermodynamics for the dismutation process, such conditions favor high kcat(O2d). Once the electron-density of Mn
center gets overly reduced, E1/2 of Mn(III)/Mn(II) redox couple 4þ450 mV vs NHE, the compound becomes stabilized in Mn þ2 oxidation state (the right arm of the bell-
shape curve). The consequence of this is that Mn(II) porphyrins are unstable (Mn gets easily lost) and are therefore not prospective therapeutics. Under such conditions the
1st and 2nd steps of dismutation process are reversed. With Mn(II) porphyrins, as the E1/2 becomes too positive, the 1st step of dismutation (oxidation of MnIIP to MnIIIP and
reduction of O2d to H2O2) becomes unfavorable and rate limiting; in turn the kcat(O2d) decreases again (the right arm of bell-shape curve). Adapted from [3].
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increasingly appreciated (Scheme XV).Differential (therapeutic) effects of MnPs on cancer vs normal
cell
Differential effects of MnPs in cancer vs normal cell have been
shown and reported in a number of cellular models (Schemes XVI
and XVII).Differential (therapeutic) effects of MnPs on cancer vs normal
tissue in animal models
Differential effects of MnPs in cancer vs normal cell have also
been shown and reported in a number of animal models. Radio-
protection of salivary glands and mouth mucosis in non-tumor
bearing mice receiving daily MnTnBuOE-2-PyP5+ treatment was
recently demonstrated. At the same time, radiosensitization of
head and neck tumor in a sc mouse tumor xenograft model was
demonstrated [Ashcraft et al., unpublished]. The radioprotective
effects of MnPs have been demonstrated in numerous other
models as well. Most striking data were obtained with mouse
prostate radiation with complete reversal of radiation-induced
erectile dysfunction (ED) ([65], Koontz, Batinic-Haberle, Tovmas-
yan et al., unpublished). Such treatment has a chance to reduce
prostate radiation-induced ED which would encourage the menScheme VII. Compounds with kcat(O2d) lower than the value for O2d self-dismutatio
simple answer is: yes. In addition to other groups, our group has also reported therapeut
mimic. The nature of the actions of this compound resulting in therapeutic effects is no
highly oxidizing and reportedly oxidize even fairly inert compounds such as MnTBAP3
MnIIIP with O2d affecting in turn the in vivo levels of O2d and restoring physiological
reductants also (Schemes XI and XII). This being said, the accurate assignment of the effec
relations between the redox reactions of those compounds and redox-based pathways o
what kind of drugs may be the best therapeutics.with prostate cancer, who have thus far been reluctant, to undergo
radiation therapy. Scheme XVII describes the data on the radio-
protection of a normal brain in non-tumor bearing mice and
radiosensitization of brain tumor in a mouse sc glioma xenograft
model [53] (Scheme XVIII).Impact of MnPs on cellular transcription
At present stage of our knowledge, the direct reactions of MnPs
with thiols of transcription factors, such as NF-κB or Keap1/Nrf2,
and/or coupled to other species, may present major contributions
to the therapeutic efﬁcacy of MnPs. In addition to direct reactions,
the indirect impact of MnP on NF-κB via scavenging reactive spe-
cies, which would have otherwise signaled its activation, cannot
be ruled out [53] (Scheme XIX).Suppression of cellular energetics of a cancer cell with MnPs
S-glutathionylation of complexes I, III and IV of mitochondrial
electron transport chain with subsequent inactivation of com-
plexes I and III and suppression of ATP production of lymphoma
cells when those were treated with MnP/dexamethasone was re-
ported by Tome’s group [45]. In addition to the radiosensitizing
actions of MnPs, such chemosensitization may further contribute
to their anticancer effects [3] (Scheme XX).n, i.e. below 5.7 are not SOD mimics. Can non-SOD mimic be a good therapeutic?A
ic effects of MnTBAP3 which has a very low log kcat¼3.16 and is thus not an SOD
t yet understood. Some of the reactive species, such as ONOO (see Scheme X), are
, AEOL11207 or MnTCHPþ . The resulting O¼MnIVP species may be reduced back to
redox environment. Reduction of O¼MnIVP species to MnIIIP may occur by cellular
ts observed in vivo is needed as that would ultimately help us in understanding the
f a cell. This will in turn positively affect drug development helping us understand
Scheme IX. Reactivity of Mn(III) ortho N-substituted pyridylporphyrins towards different low-molecular weight reactive species. In late 1990s, along with growing
awareness of highly oxidizing species, ONOO–, it became obvious that all potent SOD mimics can effectively reduce ONOO either one- (if starting from MnIIIP) or two-
electronically (if starting from MnIIP), producing either highly oxidizing dNO2 or benign NO2
 , respectively. The ONOO reduction by MnP is only few-fold slower than the catalysis
of O2
d dismutation, demonstrating that all potent SOD mimics are potent peroxynitrite scavengers. Compounds which cannot dismute O2d , such as MnTBAP3 , could be
oxidized with strong oxidant, such as ONOO , in a 1st step and reduced with either ascorbate or thiol or O2d in a 2nd step. If O2d is involved in a 2nd step, such
compounds can affect in vivo levels of O2d . Yet, the lower the SOD-like activity, the lower is the ability to reduce ONOO . Indeed, MnTBAP3 is 2 orders of magnitude less
able reductant of ONOO than is MnTE-2-PyP5þ . Coupling of ONOO reduction to O2d oxidation, has been explored with MnTM-4-PyP5þ [25], and may be operative with
other compounds. Coupling of ONOO reduction to cellular reductants is likely operative with potent SOD mimics also (Scheme X). Due to high levels of carbonate in vivo,
ONOO forms an adduct with CO2. The ONOOCO2 adduct degrades to CO3d and dNO2 radicals. Due to its radical nature, all potent SOD mimics react rapidly with CO3d in
a pH-dependent manner, log kred(CO3d-) ranging between 8 and 9 (Scheme X, Eqs. 5 and 6). Most of the rate constants provided here were based on those determined for
MnTE-2-PyP5þ . The linear relationship between log kcat(O2d) and log kred(ONOO) allows for calculations of other kred(ONOO) (see Scheme XIV).
Scheme VIII. Fe porphyrin-based SOD mimics. Fe porphyrins and Fe complex with shrunk porphyrin, corrole, which is missing a methine group at one meso position, are
listed here. Cationic Fe(III) N-substituted pyridylporphyrins (FePs) have different chemistry from Mn analogs. Both have same conformation with two axially ligated aqua
ligands, but under different conditions. Such conformation of FeP exists at pH~2, but not at pH¼7.8. The E1/2 of (H2O)2FeTE-2-PyP5þ is 160 mV more positive than E1/2 of
(H2O)2MnTE-2-PyP5þ . Thus, at pH=7.8, one aqua ligand of FeP gets deprotonated: (OH)(H2O)FeTE-2-PyP4þ is formed. MnP however has two aqua ligands at pH=7.8. Aqua
ligands are not indicated in formulas in this review (unless involved in reactions) though all Mn(III) porphyrins bear 2 aqua ligands at pH=7.8, while all FePs discussed here
have one hydroxo and one aqua ligands. The presence of electron-donating hydroxo ligand stabilizes Fe in þ3 oxidation state. This results in a shift of E1/2 from þ380 to
þ215 mV vs NHE. Consequently, the E1/2 becomes identical to the one of MnTE-2-PyP5þ (þ228 mV vs NHE); thus MnPs and FePs have similar SOD-like activities [17,18].
Another difference, FePs undergo faster degradation in vivo than MnPs. At r1 mM concentration, FeTE-2-PyP5þ is as efﬁcacious as r1 mM Fe(II) citrate in protecting aerobic
growth of SOD-deﬁcient E. coli. That is due to the release of Fe from Fe porphyrin which subsequently restores Fe-bearing proteins which have lost Fe due to the superoxide-
mediated oxidative damage. At 20 mM, though, where MnP is efﬁcacious, FeP is toxic. FePs have been successfully used in many animal models even at fairly high con-
centrations similar to those of MnPs [3,18–20]. One of them, INO-4885 is in clinical trials. Another porphyrin-like class of compounds with therapeutic potential – Fe corroles
– has been explored by Gross’s group [8,21]. Some members of corrole class, including FeTrF5Ph-β(SO3)-corrole2 , are advancing towards clinic.
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mechanism(s)
Oxidative modiﬁcation of Keap1 thiols with subsequent acti-
vation of Nrf2 and upregulation of endogenous antioxidative de-
fenses was shownwith another class of SOD mimics, M40403 [72].
Such data along with results shown in Scheme XXI strongly sug-
gest that MnP could act in a similar manner as inducer of en-
dogenous antioxidative defenses. The upregulation of different
SOD enzymes in rat kidney ischemia/reperfusion injury strongly
suggests that MnP does not act as SOD mimic. A lipophilic analog,
MnTnHex-2-PyP5þ was tested.MnTBAP3- – the actions behind its therapeutic effects are still
largely unknown
See Scheme XXII.Bioavailability – pharmacokinetic studies
Scheme XXIII.
Targeting mitochondria
Due to the critical role mitochondria has in all organisms, the
compounds that are able to cross two mitochondrial membranes
and preferentially target its matrix have been sought. Excellent
work has been done on the basics of mitochondrial transport by
Skulachev's and Murphy's groups [87,88]. Based on their research,
the essential properties of mitochondrially-targeted drug are
identiﬁed to be cationic charge and lipophilicity. Most efﬁcacious
MnPs bear penta-cationic charge. Moreover the lipophilic analogs
bear long hydrophobic substituents. Such facts justiﬁed extensive
studies of mitochondrial accumulation [80–82,89]. We have de-
monstrated that MnPs accumulate in mouse heart mitochondria,
and those that are more lipophilic do so to a higher extent than the
hydrophilic compounds, such as MnTE-2-PyP5+. Lipophilic
MnTnHex-2-PyP5þ and MnTnBuOE-2-PyP5þ were found in mouse(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11a)
(11b)
(12a)
(12b)
(13)
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drophilic MnTE-2-PyP5þ in brain mitochondria as its levels were
below LCMS/MS detection limit [90]. The mitochondrial/cytosolic
ratios of MnTnHex-2-PyP5þ and MnTnBuOE-2-PyP5þ in heart and
brain mitochondria are similar [68]. The remarkable impact of li-
pophilicity on the accumulation of cationic MnPs in mitochondria
relative to cytosol of Saccharomyces cerevisae is shown in
Scheme XXIV.
Diminishing toxicity
While most of the requirements for a good MnP-based redox-
active drug are met, lowering MnP toxicity remains a challenge.
Since, most but not all MnPs cause acute toxicity due to the blood
pressure drop (BPD), we are far away from understanding that
phenomenon. MnPs and FePs of similar redox properties but dif-
ferent lipophilicities and polarities, and with differently hindered
cationic charges, that may affect their interactions with biomole-
cules, induce BPD of different magnitude. Some, such as
(OH)FeTnHex-2-PyP4+ and (OH)FeTnBuOE-2-PyP4+, for reasons not
yet understood, do not cause BPD. However, their Mn analogs, with
similar kcat (O2d), cause BPD [18]. MnPs that are of relatively high
lipophilicity, such as MnTnHex-2-PyP5+ and MnTnBuOE-2-PyP5+,
cross blood brain barrier to signiﬁcant extent and tend to damage
membranes and become toxic at higher levels. Therapeutic window
needs to be identiﬁed for each MnP. The most frequently studiedScheme X. Reactions of Mn(III) ortho N-substituted pyridylporhyrins with different reactive
been studied and rate constants determined [3]. Most of those have been determined with fre
in vivo and await exploration. Peroxynitrite reduction with MnP: Are Mn(III) and Fe(III) porphyr
the best of our knowledge none of them are speciﬁc to ONOO [20]. Most compounds report
also) [20]. Secondly, the reported rate constants for Mn porphyrins relate to the reduction of ONOO
ONOO). What happens in vivo is another story and type of process involved (catalytic with F
ONOO; very likely MnP will be reduced with abundant cellular reductants (Eq. (3)), most so
cycle. This would happen only if MnP encounters ONOO in its immediate neighborhood and
high kred(O2) and the higher in vivo levels of oxygen than ONOO , could occur with oxygen,
catalytic rate constant was reported; same may be valid for other similar FePs [26]. Oxidatio
ONOO or ClO . However, given the orders of magnitude higher in vivo levels of O2, such r
reductants, most so with ascorbate (see Scheme XII). Oxidation of dNO with MnP – nitrosylatio
MnIIP4þ with dNO (Eqs 8 and 9) [27]. MnIIIP may be reduced in a slow reactionwith dNO (Eq. (
step followed by nitrosylation (Eq. (9)) of MnIIP4þ to give rise to (NO)MnIIP4þ in a 2nd step. Gi
with MnIIP may be better described as [(NOþ)MnIP3þ]4þ . The (NO)MnIIP4þ species is not
oxidized to nitrite and/or nitrate [28]. Possibly (. NO)MnIIP4þ , formed rapidly, may serve as a d
Doctorovich’s group, the reaction of MnP with HNO gives rise to the same product as reaction
act in a catalase-like fashion (2-electron reduction and oxidation of H2O2, Eq.11) has been dem
is 5.6 M1 s1 for MnTBAP3 . The kcat(H2O2) for FeTE-2-PyP5þ is 803 M1 s1. The most po
BothMnPs and FePs could undergo similar turnovers: slower oxidative degradation of MnPs co
happen in vivo due to high levels of cellular reductants; the catalytic cycle may be closed by
scenario H2O2 would still be eliminated/reduced to water in a 1st step. The dismutation may
ligand [8,33]. It has 10-fold higher kcat(H2O2) than FeTE-2-PyP5þ [33,34]. It also has highe
ligand vs di-anionic nature of porphyrin ligand. In turn, Fe(III) corrole can dismute larger quant
may be different than that of either FeP or MnP. For example, Fe(III) corrole, due to the stabil
reductants. The coupling with cellular reductants could happen only in a 2nd reduction step
either O2d or ONOO . The relevance of such coupling and the biological relevance of catalys
group, [35]) needs to be carefully explored. Most so in the light of recent data which indicate t
in a pro-oxidative and catalytic manner (see below), presumably in glutathione peroxidase or
that in a ﬁrst step H2O2 is reduced with MnP which in essence represents elimination of H2O2
major actions of metalloporphyrins or metallocorroles in vivo. Further, none of such compound
extent. Further studies are needed to address the issue of the advantage of higher kcat(H2O2) of
therapeutic advantage of Fe corroles over Mn porphyrins [35]. Reduction of lipid reactive species
that MnIIIP scavenges lipid reactive species whereby preventing lipid peroxidation. However
proteins were exposed to low ﬂux of ONOO , the 5 mM MnTE-2-PyP5þ , MnTnOct-2-PyP5
hydroperoxide in the presence of uric acid. The most lipophilic MnTnOct-2-PyP5þ was the mo
efﬁcacious thanMnTE-2-PyP5þ . Also α and γ tocopherol were spared. Yet in the absence of uri
more so with more redox-active cationic MnPs than with MnTBAP3 [36]. Similar impact of
Hypochlorite reduction with MnP. While only preliminary data are collected on MnTalkyl-2-Py
towards ONOO [38,39]. The reaction described by Eq. (13) is based on the Umile et al. datacompound with excellent safety/toxicity proﬁle, MnTE-2-PyP5þ ,
[92] has two “weaknesses”: (i) low transport across the blood brain
barrier which reduces its chances to be used for treatment of CNS
injuries, and (ii) short patent life of only 4 years which precludes
Pharma’s investment into its development.Therapeutic effects
What controls the magnitude of MnPs therapeutic effects?
Bioavailibility and redox properties control therapeutic effects.
Redox properties are best described with E1/2 for MnIIIP/MnIIP redox
couple which controls log kcat(O2d), i.e. SOD-like activities of
MnPs (Scheme XV, plot A). E1/2 describes best the electron-density
of metal site. Electron-density of MnP in turn controls
(i) predominantly outer-sphere electron transfer in O2d dis-
mutation and (ii) propensity of Mn center to bind other stronger
oxidants (ONOO , ClO , H2O2, CO3.) in a 1st step which is fol-
lowed by electron transfer in a 2nd step. Thermodynamics of
electron transfer, which involves either Mn þ3/þ4 or Mn þ3/þ5
oxidation states, seems to be similar for all MnPs. In turn, E1/2 of
MnIIIP/MnIIP redox couple (which involves Mn þ3/þ2 oxidation
states) parallels SOD-like and all other activities of MnPs thus far
explored (see Schemes X and XV). Bioavailability describes levels
(concentrations) of MnPs at targeted sites (organs and cellularspecies presented by equations. A number of reactions whose equations are listed have
quently explored MnTE-2-PyP5þ . It is very likely that many other reactions are possible
ins speciﬁc peroxynitrite decomposition catalysts? Simple answer – they are not. Firstly, to
ed as peroxynitrite decomposition catalysts are potent SOD mimics also (see Scheme XV
 only (Eqs. (1) and (4)), and are not of catalytic nature and cannot be described as log kcat(
eTM-4-PyP5þ or non-catalytic with MnTE-2-PyP5þ) may be irrelevant in elimination of
with ascorbate, and will then reduce ONOO in a 2nd step (Eq. (4)), closing the catalytic
at high enough concentration. The second re-oxidation step of MnIIP4þ , given the fairly
O2 and will give rise to O2d and subsequently H2O2. For FeTM-4-PyP5þ , however, the
n of MnP with oxygen. Reactivity towards oxygen, O2 is much lower than towards O2d
eactivity may play a role and be a critical step in the interactions of MnPs with cellular
n of MnP. The report by Meyer et al. tempted us to study the reactions of MnIIIP5þ and
8)). Yet, in vivoMnIIIP5þ would rather be reduced rapidly with ascorbate (Eq. (3)) in a 1st
ven the electron deﬁciency of Mn center, the distribution of electron in a complex of dNO
very stable and under aerobic conditions releases dNO slowly which subsequently gets
epot for slow release of dNO. HNO oxidation with MnP  nitroxylation of MnP: reported by
of MnP with dNO [29]. Catalase-like activity of MnP:A poor ability of 13 Mn porphyrins to
onstrated. MnTE-2-PyP5þ has the highest kcat(H2O2)¼63M1 s1. The lowest kcat(H2O2)
tent MnPs and FePs have only 0.006% and 0.06% of catalase enzyme activity [30–32].
mpensates for their lower kcat(H2O2). The catalysis of dismutation byMnPs, is unlikely to
the reduction of oxo species in a 2nd step with cellular reductants, [35] Eq. (2); in such
also involve O=MnIVP/MnIIIP via Eq. 12. Fe corrole is a complex with shrunk porphyrin
r turn-over number, due to higher stability resulting from tri-anionic nature of corrole
ities of peroxide relative to either MnPs or FePs. The overall behavior of Fe corrole in vivo
ization of higher oxidation state, cannot be reduced in vivo to Fe(II) corrole with cellular
once Fe(III) corrole is in a ﬁrst step oxidized to higher (þ4 or þ5) oxidation state with
is of H2O2 by metallocoroles, and the possible advantage over MnPs (claimed by Gross’s
hat MnPs, rather than removing H2O2, take advantage of it. Thus MnPs couple with H2O2
thiol oxidase fashionwhile imparting therapeutic effects (see Schemes XI and XIV). Note
(Scheme XIA). Such interactions vs H2O2 dismutation may be major or at least one of the
s would experience H2O2 concentrations high enough to degrade them to any signiﬁcant
Fe corrole (Scheme VIII) over MnPs, which has been used by Gross’s group to discuss the
with MnP: while those reactions have not been quantiﬁed, the indirect evidence suggests
, that happens only in the presence of cellular reductants. When the low-density lipo-
þ and MnTBAP3- prevented lipid peroxidation, i.e. the formation of cholesteryl ester
st efﬁcacious and 2-fold better than MnTE-2-PyP5þ . The MnTBAP3 was 2-fold less
c acid MnPs acted as a pro-oxidant; the consumption of tocopherols was potentiated and
MnTE-2-PyP5þ on lipid reactive species has been suggested in another study also [37].
P5þ , the reactivity towards hypochlorite seems to be of the same order of magnitude as
on imidazolyl analog, MnTDM-2-PyP5þ [38].
Scheme XI. Interaction of MnPs with thiols/H2O2 in thiol oxidase or GPx fashion.
While catalase-like action may be of no in vivo relevance due to low kcat(H2O2), the
key role of H2O2 in the actions of MnPs, other than catalase-like, has already been
established and occur in reactions of MnPs with cellular reductants (see also
Schemes XIII and XIX). Note that H2O2 is reduced to water (H2O2 is eliminated) in
Scheme A, while it is generated in Schemes B and C. The GSSG species can exchange
thiol spontaneously with RSH whereby glutathionylated protein is formed. Re-
activity towards thiols may predominate in therapeutic effects of MnPs. Studies on
CNS injuries, diabetes and cancer show that oxidation of cysteines of p50 and p65
subunits by MnP (enhanced with dexamethasone as a producer of H2O2) sup-
presses/precludes the NF-κB activation and in turn suppresses inﬂammation res-
cuing the diseased cell and/or precluding the survival of cancer cell [45–49]. In
addition S-glutathionylation of cysteines of complexes I, III and IV and subsequent
inactivation of complexes I and III of mitochondrial respiration may play key role in
reducing ATP levels in tumor cell whereby suppressing tumor growth (see Scheme
XX) [46]. The impact of MnP on ATP levels via glycolysis has been demonstrated
also [50] (Scheme XVII) MnIIIP5þ can either oxidize thiols directly (B and C), un-
dergoing one-electron reduction to MnIIP4þ whereby thiyl radical is formed in a
thiol oxidase fashion; or it can act in GPx fashion while coupling with H2O2 to S-
glutathionylate thiols (A and C). Indeed, studies on lymphoma cells showed clearly
that S-glutathionylation happens only in the presence of H2O2 and GSH [45,47]. The
H2O2 may originate either from: (i) already increased oxidative stress of a cancer
cell, or (ii) additional generation via radio- or chemotherapy, or (iii) catalytic cy-
cling of MnP with ascorbate or thiols.
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charge, size, shape and bulkiness of a molecule. The reactivities and
in turn therapeutic effects are further controlled by the levels or re-
active species in immediate neighborhood of MnPs. Based on all said,
the best strategy in the design of an excellent therapeutic able to
restore normal physiological redox environment may be to:
(i) assure high metal/ligand stability, and in turn provide integrity
of metal site; (ii) target as high as possible SOD-like activity; (iii)
maintain positive charges to enhance electrostatically the reac-
tions of MnPs with predominantly anionic reactive species, while
enhancing lipophilicity. Enhanced lipophilicity would result in (iv)enhanced accumulation of MnPs at all sites abundant with anionic
phosphates such as mitochondria and brain. Importantly, the ef-
forts need to be continuously invested in (v) minimizing toxicity of
MnPs (Scheme XXV).Distinction must be made between anti- and pro-oxidative re-
actions and anti- and pro-oxidative therapeutic effects
See Scheme XXVI.SOD mimics – the story continues
The perfect therapeutic should promote adaptive responses
and help our body with upregulation of our own endogenous
antioxidative defenses. The most obvious case of such adaptive
response is demonstrated during regular physical exercising. In-
creasing number of reports support pro-oxidative actions of MnPs,
nitroxides and ﬂavonoids which result in adaptive responses.
During 2 decades of research, we have gone a long way from in-
itially viewing MnPs as antioxidants exclusively (SOD mimics) to
considering them (pro)oxidants. Interestingly enough, with data
right in front of our noses, it took us a long time to consider all
aspects of O2d dismutation process. The incorrect viewing of SOD
enzyme and its mimic as antioxidants lies in 2 facts. Firstly, the
two reactions involved in a dismutation process require a com-
pound to be equally good anti- and pro-oxidant (Scheme I). Sec-
ondly, the dismutation process produces an oxidant, H2O2. In turn,
the SODs and their mimics can only be considered antioxidative
defenses if H2O2 is removed rapidly in conjunction with catalases
or peroxidases. Such considerations help us understand that,
based on identical thermodynamics of metal centers and de-
pending upon the cellular redox environment (levels of oxidative
stress) plethora of reactions are possible with SOD enzymes and
MnPs. Yet, due to steric hindrance imposed by large protein
structure such reactions of SODs occur, if at all, with orders of
magnitude lower rate constants as compared to their small mo-
lecular-weight mimics.
A number of other issues need to be addressed as the MnPs
advance towards Clinic. How long the treatment with MnP, following
injury, should last?Will we be able to ever restore the physiological
redox status, or as soon as the therapy is discontinued some level
of inﬂammation will be re-established. Studies on CNS indicate
that the longer the treatment lasts, the longer the reduction in
stroke volume post-injury was demonstrated [93]. What are the
therapeutic concentrations of MnPs at the sites of injury? We have
only marginal knowledge how much of MnP we need in target
tissues. It seems that 30 nM brain levels afford protection with
MnTnHex-2-PyP5þ in a stroke model [94]. Yet, we do not know if
lower levels would produce such effects also. Clariﬁcation of such
issues is costly but eventually will be needed.
Several metalloporphyrins are progressing towards or are in
Clinical Trials. MnTDE-2-ImP5þ passed Safety/toxicity Phase I
Clinical Trials on ALS patients [95]. MnTE-2-PyP5þ is in ongoing
Clinical Trials, whereas STTR/NIH support has been granted for the
Phase I/II Clinical trials on Head and Neck cancer patients on
radioprotection of salivary glands and mouth mucosis. Another
STTR/NIH funding for Phase I/II Clinical Trials on radioprotection of
normal brain (with brain tumor patients) is pending. Another type
of SOD mimics, M40403, is in Clinical Trials for the radioprotection
of mouth mucosis as well. Fe porphyrin INO-4885 is in Clinical
Trials for the use in contrast-induced nephropathy [20].
Summary. We may thus conclude our story with our most re-
cent understanding that cationic Mn(III) substituted pyridyl- or
Scheme XII. Interaction of MnPs with ascorbate (NaHA–sodium ascorbate, HA- - monodeprotonated ascorbate, major species at pH 7.8). Due to high intracellular levels of
ascorbate (up to 0.1 mM), its interaction with MnP has been of our continuous interest since 1998 [3,6,17,41,43,44,51,52]. Due to its catalytic nature, such cycling generates
high levels of H2O2, which are limited by levels of either ascorbate or oxygen. H2O2 formed can alternatively oxidize MnIIP and MnIIIP to (O)MnIVP and (O)2MnVP, respectively
(Eqs. 11a and 12a), with concomitant reduction to H2O. The oxidized MnPs can be reduced back to two-electronically with HA producing dehydroascorbate (DHA). MnP/
ascorbate system carries the therapeutic potential as anticancer therapeutic strategy [3,43]. MnP will in vivo likely couple with endogenous ascorbate due to its high levels.
Yet therapeutic effects may be enhanced with exogenous ascorbate [42,44]. The system MnP þ ascorbate, with regards to its mechanism of action, resembles to other major
anticancer therapies which generate H2O2 (radiation and chemotherapy) where MnPs act as radio- and chemosensitizers [3,47,53] See also Schemes XVI–XVIII.
Scheme XIII. Interaction of MnP with tetrahydrobiopterin. Tetrahydrobiopterin is a cofactor of nitric oxide synthase, NOS. The reaction with tetrahydrobiopterin, BH4, would
result in a loss of reducing equivalents for NOS and could in turn result in NOS inhibition. Under such conditions NOS would make O2d instead of dNO. The kox1(BH4) was
found to be 1.0104 M1 s1 for one-electron oxidation of BH4 to BH4dþ and kox2(BH4dþ) 1.5103 M1 s1 for one-electron oxidation of BH4dþ to 6,7-(8H)-BH2[54].
Cycling with BH4 could result in tumor growth suppression via inhibition of its angiogenesis [54]. Recovery of MnP catalyst may lead to H2O2 production via Eq. (7).
Alternatively, BH4 may be oxidized with high-valent, highly oxidizing O=MnIVP4+ species formed in reactions with ONOO or H2O2 (Eqs. (1) and (12a)).
Scheme XIV. Role of H2O2 in the actions of MnPs. Over years, our data have contributed to our understanding that H2O2 plays a key role in the redox biology of MnPs. The
Scheme summarizes all aspects of MnP/H2O2 interactions addressed thus far ( [3,30,31,45,47]. The direct evidence was provided that H2O2 is essential for the impact of MnP/
dexamethasone on cellular transcription and cell viability in lymphoma cellular model [45]. In such model MnP/dexamethasone system produces H2O2 which MnP employs to
S-glutathionylate NF-κB which in turn causes cellular apoptosis and reduces number of viable cells. When catalase over-expressor CAT2 and CAT38 cells were treated with
MnP/dexamethasone the identical number of viable cells was obtained as with MnP alone. Further, depletion of GSH with buthionine sulfoximine inhibitor of GSH synthesis
suppressed S-glutathionylation of NF-κB. The same effect on NF-κB inhibition, demonstrated with MnP/dexamethasone, was replicated with NF-κB inhibitor, SN50
[3,31,45,47]. The oxidation of NADH and NADPH in the presence (but not absence) of H2O2 was demonstrated in aqueous system [31]. Hydroxylation of cyclophosphamide
with MnP/asc – H2O2 generator system – was reported (see Scheme XXI) [52,55]. Adapted from [55] TPx–thiol peroxidation; TO–thiol oxidation; L-Ox–lipid oxidation; L-Px–
lipid peroxidation.
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Scheme XV. SOD-like activity parallels other reactions of MnPs thus far studied as exempliﬁed here with reduction of ONOO , oxidation of ascorbate and catalysis of H2O2
dismutation by MnP.Why potent SOD mimics are effective scavengers of other species and why in turn they may still be the most prospective therapeutic agents (assuming they are
optimized for bioavailability and toxicity)? (1) MnTBAP3 , (2) MnTE-2-PyPhP5þ , (3) MnTE-3-PyP5þ , (4) MnTE-2-PyP5þ , (5) MnTPhE-2-PyP5þ , (6) MnTnHexOE-2-PyP5þ , and
(7) MnTnOct-2-PyP5þ . In addition to those MnPs numerated, encircled in B are MnTnHex-2-PyP5þ and MnTnBuOE-2-PyP5þ and in C is MnTnHex-2-PyP5þ . The maximal
kcat(O2d) has been obtained at E1/2 for MnIIIP/MnIIP of þ200 to þ450 mV. The values of E1/2Zþ400 mV stabilize Mn in þ 2 oxidation state and either MnIIP or a very
weak MnIIIP complex is formed. At values of E1/2rþ100 mV Mn is stabilized in þ3 oxidation state to such extent that it does not favor reduction to MnIIP complex in a 1st
step in order to start the O2d dismutation. The E1/2 of around þ200 to þ400 mV vs NHE is around the E1/2 of SOD enzymes where both steps of dismutation process occur
with similar rate constants and are thus similarly thermodynamically favored. The E1/2 describes the magnitude of metal electron density which in turn reﬂects electron
density of porphyrin ligand. E1/2 of metal center thus relates to the protonation equilibria at all porphyrin sites (at pyrrolic nitrogens of porphyrin ligand and at waters axially
ligated to metal site). Two such equilibria have been quantiﬁed at: (i) 3rd inner pyrrolic nitrogen of metal-free porphyrin, pKa3 [H3Pþ↔H2PþHþ], and (ii) at 1st axially bound
waters, pKa(ax) [(H2O)2MnP5þ↔(OH)(H2O)MnP4þþHþ]. The inversed linear relationship exists between E1/2 and pKa(ax) and pKa3 each: the higher the propensity of MnP to
be reduced (the higher the E1/2), the more-electron-deﬁcient MnP is and less strongly it keeps its axial waters, thus easier (at lower pH) the proton is released and in turn the
lower is the pKa(ax). The same is true for pKa3. The more pyrrolic nitrogen favors the proton association (the higher the pKa3), the more electron-rich nitrogen is. In turn, such
electron rich porphyrin ligand favors the formation of a stable complex with Mn. That means the higher the pKa3 the less positive is the E1/2 for MnIIIP/MnIIP redox couple.
The consequence of such relationships is that the more electron-deﬁcient the Mn complex is (lower the pKa3), in addition to aqua ligand, the more it would favor binding
different ligands, such as ONOO , ClO , CO3.  and H2O2. The binding of these species comprises the 1st step in their reductions. This further explains why the rate constants
for the reduction of ONOO or ClO and H2O2 dismutation are related to the E1/2 of the MnIIIP/MnIIP redox couple though it is not involved in such reactions (Scheme XII). As
E1/2 is proportional to log kcat(O2d), the log kcat(O2d) is proportional to both log kred(ONOO) and log kcat(H2O2) as shown in plots A and C. Importantly, the E1/2 of electron
transfer which follows the binding of those species, and involves Mn þ 3/þ4 oxidation states (Eq. (1)), appears to be nearly identical for all MnPs [6,59]. In vivo, the 2nd step
may preferentially involve two-electron electron transfer between Mn þ2 and Mn þ4 oxidation states (Eq. (4)). Under such conditions, the differences in E1/2 for the
MnIIIP/MnIIP redox couple will affect the E1/2 of O¼MnIVP/MnIIP redox couple. The ability of MnP to couple with ascorbate (plot B), catalyzing its oxidation follows the same
trend as described for ONOO and H2O2, as binding of ascorbate is involved in a 1st step of ascorbate oxidation. The deviation from the linearity has been demonstrated with
compounds which have bulky pyridyl substituents (encircled in plots B and C). While not showed in plot A, the deviation from linearity has been seen also [7,10].
Scheme XVI. Differential therapeutic effects of MnP/ascorbate system on cancer (cervix cancer HeLa) vs normal cell line (human dermal ﬁbroblasts, NHDF). MnP stands here
for MnTE-2-PyP5þ . The differential therapeutic effect is based on differential redox environment of cancer vs normal cell [5,60]. Growing insight into the biology of cell and
redox chemistry of MnPs taught us that we can take advantage of the rapid coupling of MnP with abundant cellular reductants [3,6,17,41,44,51,52]. Thus far we have shown
that the catalytic oxidation of ascorbate with MnP (coupled to oxygen, Scheme XII) would enhance peroxide levels and could kill cancer without affecting much normal
tissue [3,46]. The reason lies in fact that cancer is frequently low in H2O2-removing systems (catalases, GPx, peroxiredoxins) and cannot cope with additional increase in H2O2
levels [4–6,60]. This reasoning is the same as the one behind the use of other H2O2-producing strategies: radio- and chemotherapy. Oxidation of ascorbate at the expense of
endogenous metalloproteins has already been employed in clinical trials in patients with pancreatic cancer [61,62]. The use of Mn porphyrin, MnTE-2-PyP5þ and analogs of
similar redox properties (MnTnHex-2-PyP5þ , MnTnBuOE-2-PyP5þ), optimized for ascorbate oxidation, has been reported by us [3,6,41,43,44] and subsequently by others to
bear therapeutic potential [40,42,63]. The cytotoxicity of MnP/ascorbate has been shown with several other cancer cell lines, such as CaCo-2 (colorectal cancer), HCT116
(human colon cancer) MCF-7 (breast cancer), SUM149 (inﬂammatory breast cancer), 4T1 (mammary breast cancer), and 3 different gliomas (deltaGli36, U87MG, D-245MG)
([41,43] Batinic-Haberle I, Lam PYP, Roberts ERH et al., unpublished). Such system has been further shown by us and others not to be deleterious to normal cells [3,40,43,46].
Adapted from [3].
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cell and cancer cell to a different extent but through identical
actions – modiﬁcations of thiol-based signaling pathways. As SODpotency relates to the therapeutic effects of Mn porphyrins we
alternate between describing them as SOD mimics or redox active
therapeutics.
Scheme XVII. Differential effects of MnPs on normal vs cancer cell are controlled by their differential redox environments. Differential redox environment of normal and
cancer cells promotes differential actions of MnPs. The rising data indicate that many antioxidant systems are differently regulated in cancer cell. Thus catalases, GPx,
peroxiredoxins may be down regulated and often inactivated, while MnSOD may be upregulated which results in increased levels of H2O2 [4–6,60]. Reactions involved in the
actions of MnPs are indicated in this Scheme and Scheme XIV and occur with different yield/magnitude in normal vs cancer due to their different levels of H2O2. Thus much
larger levels of H2O2 in cancer vs normal cell would promote MnP/H2O2-driven oxidations to such extent that cancer cell would be forced to undergo apoptosis. Oxidations
and/or S-glutathionylation (in GPx fashion) of thiols of NF-κB and complexes I and III of electron transport chain by MnPs/H2O2 may predominate in vivo [45,47–49].
MnP/H2O2-driven oxidations in normal cell would be of lesser extent that in cancer cell and thus would only suppress excessive inﬂammation which would result in healing
of a normal cell [2,34,3,24]. Note: the beneﬁcial therapeutic effects we observe may be different in nature. With normal cells, healing is demonstrated and thus the effects
observed are of antioxidative nature. With cancer cells the actions of MnP/H2O2 are of magnitude high enough to cause cancer cell death: the therapeutic effects observed are
pro-oxidative. Note that the actions behind such effects are pro-oxidative with both normal and cancer cell (oxidative modiﬁcation of thiols), but due to differences in their
magnitudes the therapeutic effects observed are of different type: transient suppression of NF-κB in a normal cell similar to what is seen with aspirin and ibuprofen, but excessive
NF-κB inhibition in a cancer cell similar to effects induced with steroid therapy leading to cell death [64].
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Scheme XVIII. Radioprotection of normal brain and radiosensitization of brain tumor by MnTnBuOE-2-PyP5þ . (A) The treatment strategy for brain radioprotection with
MnTnBuOE-2-PyP5+(MnP) [53]. (B) Histological evaluation of myelinated axons in the corpus callosum. Representative images of toluidine blue-stained mid-sagittal corpus
callosum tissue were imaged by brightﬁeld microscopy (n¼3 mice/group). Groups studied were (1) Saline, (2) MnP (3) Saline / radiation (RT), and (4) MnP/RT. Toluidine
blue-stained mid-sagittal corpus callosum tissue were imaged by brightﬁeld microscopy (n¼3 mice/group). Three images from each mouse underwent automated axon
counting that is quantitated in the box graph with 95% conﬁdence intervals. ANOVA analysis of the group resulted in signiﬁcant differences among the groups (p¼0.040). (C)
The impact of MnTnBuOE-2-PyP5þ-based radiosensitization on tumor growth delay in a sc mouse xenograft D-245MG glioblastoma multiforme study. Patients-derived glio-
blastoma cells (kindly provided by The Preston Robert Tisch Brain Tumor Center at Duke University) were inoculated subcutaneously in the right ﬂank of BALB/c nu/nu mice.
Once tumors reached approximately 65 mm3 (Day 0), mice were randomly assigned to 4 groups with 8 mice per group: saline, saline/RT, MnP, and MnP/RT. Mice were
injected subcutaneously with 1.6 mg kg1 MnP twice daily (beginning at 24 h before RT and continuing for the duration of the study). Tumors were irradiated for 3 days with
1 Gy day1 on day 2–4 (XRAD-320, Precision X-ray, North Branford, CT) [53]. The impact of similar magnitude was achieved with MnP/temozolomide treatment, where MnP
acted as a chemosensitizer; the action is similar to MnP-driven sensitization of lymphoma cells to dexamethasone [45–47]. Both MnTnHex-2-PyP5þ[2] and
MnTnBuOE-2-PyP5þ suppressed tumor growth of D-245MG to similar magnitude under identical experimental conditions. Adapted from [53].
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Scheme XIX. Impact of MnPs on cellular transcription. The reactions of MnPs were thus far explored with respect to several transcription factors, NF-κB, AP-1, SP-1, HIF-1α
(see also Scheme XIV) [48]. MAPK/ERK pathway has been implicated also [41]. Oxidation of cysteine residues of p50 and p65 subunits of NF-κB by MnPs/H2O2 (the pro-
oxidative actions of MnPs) prevents the activation of NF-κB, and in turn suppresses excessive inﬂammation and thus produces therapeutic effects which we identify as anti-
oxidative [3]. Data obtained by us on MnPs (Scheme XXI) [66,67] and others on a member of other class of SOD mimics, Mn(II) cyclic polyamines, M40403 [68], suggest the
impact of MnPs on the activation of Nrf2. Upon oxidation of redox sensitive cysteines of Keap1, Nrf2 transcription factor is activated, which results in upregulation of
endogenous antioxidative defenses [67,68]. Nitroxides were shown to activate that pathway also [69–71]. It may be mechanism of actions of ﬂavonoids also [70,71] (see also
Scheme XX).
Scheme XX. MnP inactivates complexes I and III via their S-glutathionylation when combined with dexamethasone in lymphoma cellular model. MnTE-2-PyP5þ was tested
in lymphoma cellular model where it enhanced cell killing in the presence of dexamethasone via enhancing H2O2 production [45,46]. H2O2 in turn was employed by MnP to
catalyze S-glutathionylation of protein thiols. Such action, depicted in Scheme XI, is in essence either GPx- or thiol oxidase-like activity of MnP. Such oxidative modiﬁcation
has been demonstrated on both cytosolic and mitochondrial levels. In cytosol cysteine units of p50 and most so p65 of NF-kB seem to be modiﬁed, while complexes I, III and
IV were S-glutathionylated in mitochondria. Also oxidation of p50 by MnP in nucleus has been suggested by Piganelli's group [48]. All proteins except complex IV (though
S-glutathionylated) were inactivated by such oxidative modiﬁcations. That indicates that MnP under conditions of high oxidative stress, i.e. high H2O2 levels, which may be
produced by different treatment modalities such as radiation and chemotherapy (dexamethasone or ascorbate or temozolomide, [3,41,42,44,45,47,53], would suppress anti-
apoptotic, survival pathways and cellular energetics, killing cancer cell on two metabolic fronts. Adapted from [45,46].
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Scheme XXI. Increase in antioxidative genes due to MnP-based treatment of rats which underwent kidney ischemia–reperfusion I/R. The GPMmixture treatment contained:
bFGF, recombinant EPO, SDF-1 and BMP-7, and a mixture of mitochondria protective amino acids, including α-ketoglutarate and L-aspartic acid, and MnTnHex-2-PyP5þ [67].
Note that major endogenous antioxidative defenses are up-regulated indicating that MnP under given conditions could not have acted as SOD mimic. During I/R the H2O2 is
produced which MnP supposedly employs for oxidative modiﬁcations of protein thiols as indicated in other studies (Schemes XI, XIV and XX). We hypothesized that in this
model MnP oxidizes Keap1 cysteine and in turn activates Nrf2 which then upregulates endogenous antioxidative defenses. Indeed the Keap1 oxidation and Nrf2 activation
were implicated with another class of SOD mimic, M40403 [68], nitroxides, curcumin [73] and ﬂavonoids [70,71]. The following groups, with 10 male Sprague–Dawley rats
each, were studied: (a) sham-operated; (b) I/R with saline only; (c) I/R with growth factors only (G); (d) I/R with MnP only (P); (e) I/R a mixture of α-keto-glutarate and L-
aspartic acid (M), and (f) GPM mixture. GPM was given 24 h before 40-min ischemia and 24 h post-reperfusion. The study was terminated at 48 h post-reperfusion. Periodic
acid –Schiff (PAS) stains and tubular damage grading was assessed at 48 h post-I/R. All individual components of GPM mixture produced beneﬁcial effects which were lower
than those produced with whole GPM mixture. (A) Normal PAS staining of non-ischemic sham operated left kidney; (B) dramatically increased PAS positive necrosis in
ischemic left kidney; (C) reversal of necrosis in ischemicþGPM treated left kidney; (D) signiﬁcant decrease in the acute tubular necrosis grading in ischemic left kidney
treated with the GPMmixture (po0.0003). In next kidney I/R study, the authors introduce N-acetyl cysteine into the GPMmixture; all effects were enhanced; note that MnP
cycles with thiols producing H2O2 (Scheme XI) [66,67]. Adapted from [67].
Scheme XXII. MnTBAP3 , while not an SOD mimic, produces therapeutic effects. The therapeutic effects have been reported in all cases listed in the Scheme, other than in
cancer and in O2d-speciﬁc aerobic growth of E. coli and S. cerevisiae. The impure MnTBAP3 obtained from Alexis or Calbiochem has often been used in past [74]. It
contained SOD-active Mn oxo/hydroxo/acetato complexes; in turn the origin of effects has been dubious [75]. Still even when pure MnTBAP3 was used the therapeutic
effects have been observed, though of lesser magnitude relative to cationic Mn(III) N-substituted pyridylporphyrins [4,76,77]. 50 nM MnTE-2-PyP5+, 1 µM FeTM-4-PyP5+
while 100 µM MnTBAP3– were able to attenuate ATN-224-induced peroxynitrite-dependent death of lymphoma cells which are oxidative stress-resistant and are over-
expressing Bcl-2. ATN-224 is a Cu chelator, choline tetrathiomolybdate, that reduces the activity of Cu,ZnSOD enzyme. While not an SOD mimic, MnTBAP3 reduces ONOO ,
thus exhibiting some speciﬁcity towards elimination of ONOO over O2d [77]. This suggests that much about its in vivo actions awaits further clariﬁcation. In a rat spinal
cord ischemia/reperfusion model, under same dosing regime, MnTBAP3 suppressed NF-κB expression as does a powerful SOD mimic, MnTnHex-2-PyP5þ . Such action
prevented excessive NF-κB-driven inﬂammation [4]. The dose-dependence and the mechanism behind NF-κB inactivation by those MnPs are under further investigation.
Adapted from [4].
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Scheme XXIII. Pharmacokinetic and bioavailability studies with MnPs. Bioavailibilities of MnPs depend upon their lipophilicities, polarities, charge, size, shape, and
bulkiness. Comprehensive studies have been reported on MnPs that bear similar redox properties (MnTE-2-PyP5þ , MnTM-2-PyP5þ , MnTnBu-2-PyP5þ , MnTnHex-2-PyP5þ
and MnTnBuOE-2-PyP5þ in different organisms via various administration routes. The PK studies involved plasma and different organs such as liver, kidney, lungs, spinal
cord, brain, spleen, heart, colon, salivary glands and tongue. Also intracellular accumulation has been addressed on ZnPs and MnPs and data published on membrane,
cytosolic, nuclear, mitochondrial, endoplasmatic reticular and lysosomal accumulation [78–83]. Largest body exposure of MnPs, expressed as AUC (area under pharmaco-
kinetic curve) has been obtained via subcutaneous route; this route also has another advantage as it imposes the lowest acute side effects in MnP administration  blood
pressure drop. Highest levels of MnPs are found in liver and kidneys (at µM levels), while the lowest were detected in brain (at nM levels). Lipophilic and cationic,
MnTnHex-2-PyP5þ and MnTnBuOE-2-PyP5þ accumulate several fold more in brain (driven there by the anionic phospholipids) than does hydrophilic MnTE-2-PyP5þ
[Spasojevic, Tovmasyan, Weitner et al., unpublished]. Given the highly positive charge, MnTE-2-PyP5þ accumulates 3-fold more in nucleus than in cytosol of macrophages
and LPS stimulated macrophages [48]. Such accumulation seems to be important given the suggestion by Tse and Piganelli that MnP oxidizes p50 in nucleus [48,49]. Cationic
MnPs were also found to favor accumulation in cell wall of E. coli due to abundance of negatively charged phospholipids [84]. Extensive distribution studies of ﬂuorescent Zn
analogs using confocal ﬂuorescent microscopy indicate their accumulation in membranes, lysosomes and endoplasmatic reticulum also [78,85]. The study was carried out on
adenocarcinoma cells where lipophilic ZnTnHex-2-PyP5þ was also found in mitochondria in the vicinity of cytochrome c oxidase [79]. The only difference between Zn and
Mn analogs is the lack of single charge on Zn center. Yet, with longer alkyl analogs, such as MnTnHex-2-PyP5þ no difference in their lipophilicities exists as single cationic
charge on Mn is shielded from the solvent by long hexyl chains. Moreover, in vivo MnPs get readily reduced with cellular reductants, lose single charge on metal site and
become similarly hydrophilic as ZnPs [86]. Thus, accumulation data on ZnPs (in particular those with long alkylpyridyl substituents) can be readily applied to MnPs.
Scheme XXIV. Impact of lipophilicity on mitochondrial vs cytosolic accumulation of cationic MnPs in S. cerevisiae. Impressive levels of otherwise hydrophilic compounds
were found in mitochondria relative to cytosol and are presumably due to their high penta-cationic charge. The striking impact of lipophilicity on their mitochondrial
accumulation was demonstrated [91]. Even the most hydrophilic MnTM-2-PyP5þ and MnTE-2-PyP5þ prefer mitochondria to cytosol. Such data suggest that pentacationic
charge, rather than lipophilicity of pyridyl alkyl chains, controls mitochondrial accumulation of MnPs.
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Scheme XXV. Therapeutic effects of MnPs. The O2d speciﬁc models of SOD-deﬁcient single-cell pro- and eukaryotic organisms, E. coli and S. cerevisiae, are the ﬁrst and
major steps in evaluating therapeutic potential of MnPs. Once they are successfully tested in unicellular organisms, MnPs are forwarded to various cellular and animal
models. During the last two decades numerous cellular and animal studies (on mice, rats, rabbits and monkeys), conducted on models of diverse diseases, support re-
markable therapeutic potential of metalloporphyrins; thus we hope that some will successfully Clinical Trials. Therapeutic effects demonstrated in models of CNS injuries,
immune disorders, cancer and radioprotections were summarized in several manuscripts of Forum Issue “ SOD therapeutics” of Antioxidants & Redox Signaling 2014.
Scheme XXVI. MnPs undergo anti- and pro-oxidative reactions which may be demonstrated either as anti- or pro-oxidative therapeutic effects. While such reasoning and
experimental data behind it have been a main theme across this review, it is important to stress it here again: researchers need to differentiate between the type of reactions
of MnPs and nature of therapeutic effects they observe. For example, oxidation of cysteines of NF-kB by MnP suppresses its activation which in turn suppresses secondary
oxidative stress. This is demonstrated as reduced inﬂammation – commonly accepted as anti-oxidative therapeutic effects. Further, the oxidation of cysteine of Keap1 by MnP
would activate Nrf2 which would upregulate endogenous antioxidative defenses (catalases, SODs, peroxidases, etc) in an adaptive response. This would result in suppression
of inﬂammation –clear case of antioxidative effect. Again pro-oxidative reaction of MnP results in anti-oxidative therapeutic effects. Please note that not all reactions thus far
studied are listed in this Scheme, such as reactions with tetrahydrobiopterin, H2O2 and CO3d (for further information see other chapters). Many more in vivo reactions of
MnPs are likely yet to be identiﬁed.
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